Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. This morning Marinus Pharmaceuticals Inc. (MRNS:NASDAQ) , a pharmaceutical firm dedicated to...
Streetwise Reports | September 27, 2019 |

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). This morning orphan lun...
Streetwise Reports | January 2, 2020 |

Building a Better Healthcare Solution Amid Great Demand

(Click image above to play video) Welcome to the one-stop shop for remote in-home health monitoring. Soon-to be publicly-listed Cloud DX Inc. ( TSX-V.ROSV.P , Forum ) is an innovative, cutting-edge company that offers ‘The Connected Health Kit&CloseCurlyQuot...
Dave Jackson | March 18, 2021 |

DNI Metals | Status on Trading, Fraud Trial, and Permits

DNI Metals (CSE: DNI | OTC: DMNKF) Dan Wei r of DNI Metals sits down with Maurice Jackson of Proven and Probable to provide shareholders updates on when trading will commence on the Canadian Stock Exchange, judicial ma...
Maurice Jackson | April 1, 2020 |

Buzz on the Bullboards: Bulls on the Buzzboards

Do you believe in parallel dimensions, alternate realities? Somewhere where there is no COVID, European tensions are just that – tense, market volatility is kept to a minimum. It is here, perhaps, in the inversed Buzz, where everything is “fine”...
Stockhouse Editorial | March 9, 2022 |

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. In a June 11 research note, Dawson James analyst Jason Kolbert reported that Pluristem Therapeutics Inc. (PSTI:NASDAQ) announced the status of COVID-19-infe...
Streetwise Reports | June 18, 2020 |

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. Clinical-stage biopharmaceutical company Mersana Therapeuti...
Streetwise Reports | May 28, 2020 |

Biopharma to Test Immunity Activator in Advanced Solid Cancers

The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. In a Dec. 12 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) plans to ...
Streetwise Reports | December 19, 2019 |

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...
Streetwise Reports | May 28, 2020 |

Buzz on the Bullboards: Cancer Detection of the Future … Today

(Image via StageZero Life Sciences Ltd.) Even though there is a wide buffet of rich investing opportunities out there that are of high appeal to serious investors and small-cap opportunists in the current market, COVID-19 movements still take the cake. Over the ...
Stockhouse Editorial | April 14, 2021 |
1 2 3 4 5 6 7 8 9 10 ...